Originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants and microorganisms) into novel therapies, Nintx (Next Innovative Therapeutics) believes plant-based natural products bear huge potential to serve as a superb platform to modulate human biological targets and the microbiome concomitantly, affording therapies for multifactorial diseases (multi-target therapies).
Nintx was founded by two experienced PhD scientists, Dr. Miller Freitas (CEO) and Dr. Cristiano Guimarães (CSO), who are the main executives of the company, and Mr. Stephani Saverio, MBA, a healthcare veteran who has been acting as a Non-Executive Board Member for the startup.
Nintx is a startup with innovation as core business, right at the center of the strategy, heavily based on advanced technologies, coupled with the Brazilian biodiversity, the most biologically diverse in the world, to develop the next generation of therapies. Some of Nintx’s proprietary technologies include xGIbiomics®, which closely emulates the human gastrointestinal digestive system and microbiome, and GAIApath®, an artificial intelligence and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome concomitantly. Nintx’s cutting-edge technologies and concepts will be key in the future development of multi-target therapies.


Biotechnology

Life Sciences

Therapeutics

Nintx

Nintx's headquarters in São Paulo, Brazil

People (7)

Jobs (0)

Other offices